Press releases

HEALTH CANADA APPROVES OTSUKA AND LUNDBECK'S REXULTI^TM (brexpiprazole) AS A TREATMENT FOR SCHIZOPHRENIA IN ADULTS - February 17, 2017

LUNDBECK CANADA’S CONTRIBUTION TO UNIVERSITE LAVAL’S FACULTY OF PHARMACY AND CREATION OF A MASTER OF ADVANCED STUDIES IN PSYCHIATRY IN PARTNERSHIP WITH THE IUSMQ  - October 5, 2014

LUNDBECK ANNOUNCES HEALTH CANADA APPROVAL OF TRINTELLIX™ (vortioxetine hydrobromide) FRO THE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER - October 28, 2014

NEW ONCE-MONTHLY TREATMENT FOR SCHIZOPHRENIA, ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension), NOW AVAILABLE IN CANADA - May 5, 2014

LUNDBECK CANADA LAUNCHES A NEW TREATMENT FOR A RARE FORM OF ACUTE LEUKEMIA- November 13, 2013

LUNDBECK CANADA OFFERS NEW TREATMENT OPTION FOR RELAPSED INDOLENT B-CELL NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
- September 13, 2012

LUNDBECK CANADA HAILS NEW NATIONAL STANDARD ON PSYCHOLOGICAL HEALTH AND SAFETY IN THE WORKPLACE
- January 16, 2013

Members of the media seeking further information may contact:
Stella Antonaras
Corporate Communications Specialist, Public Affairs
Tel 514-844-8515
STLL@Lundbeck.com

For Customer Service inquiries, please contact:
Danielle Beauchesne
CNS Representative, Customer Service
Tel 1-866-610-8338
CanadaCustomerService@Lundbeck.com